Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;8(1):e000479.
doi: 10.1136/lupus-2021-000479.

SARS-CoV-2 vaccines in patients with SLE

Wei Tang  1 , Anca D Askanase  2 , Leila Khalili  1 , Joan T Merrill  3
Affiliations

SARS-CoV-2 vaccines in patients with SLE

Wei Tang et al. Lupus Sci Med. 2021 Mar.

Erratum in

Abstract

As the Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) vaccines become available to patients with autoimmune diseases and SLE, practitioners will have to inform them about the safety and efficacy of these vaccines. Here we discuss the challenges of applying vaccine data to patients with autoimmune diseases and the evidence available in the literature that may help in the decision process.

Keywords: inflammation; lupus erythematosus; systemic; vaccination.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Johns Hopkins University coronavirus resource center, COVID-19 dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins University 2021.
    1. Postal M, Vivaldo JF, Fernandez-Ruiz R, et al. . Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol 2020;67:87–94. 10.1016/j.coi.2020.10.014 - DOI - PMC - PubMed
    1. Weckerle CE, Franek BS, Kelly JA, et al. . Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum 2011;63:1044–53. 10.1002/art.30187 - DOI - PMC - PubMed
    1. McNab F, Mayer-Barber K, Sher A, et al. . Type I interferons in infectious disease. Nat Rev Immunol 2015;15:87–103. 10.1038/nri3787 - DOI - PMC - PubMed
    1. Hadjadj J, Yatim N, Barnabei L, et al. . Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020;369:718–24. 10.1126/science.abc6027 - DOI - PMC - PubMed

MeSH terms

Substances